{
  "docId": "019de075-e8f5-748b-98ae-3f4a3c3c68f5",
  "docSlug": "5bc6ecf6756c39ce2bfe560c6ffb0fc7",
  "documentTitle": "ATAI | Investor Presentation Deck | 31 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 31,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "Includes a map of global disease burden and key product specs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e8f5-748b-98ae-3f4a3c3c68f5/23",
  "deckHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5",
  "deckJsonHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5.json",
  "deckAnchorHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "1. World Health Organization; 2. Anxiety and Depression Association of America (2021); 3. GlobalData (as of 6/1/2023)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45042e1c-f7ac-489a-ae9e-6f2c8c972099",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.52,
        "y": 0.6
      },
      "kind": "image",
      "text": "Global disease burden map",
      "attrs": null,
      "subkind": "map",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f06c2623-8a20-40b4-add6-810772e147fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.52,
        "y": 0.27
      },
      "kind": "list",
      "text": "Anxiety disorders develop when feelings of apprehension and unease persist; 50% of US patients go untreated; No FDA approved novel treatments over the past decade",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "773770fa-451a-4bab-af9a-439951763b41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.48,
        "x": 0.02,
        "y": 0.55
      },
      "kind": "list",
      "text": "Demonstrated rapid onset; Review of ~14m prescriptions in France; Differentiated tolerability profile",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a81cf08b-9722-48c0-8277-e99d8a8731e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.8,
        "y": 0.75
      },
      "kind": "metric",
      "text": "#1 Most common mental health disorder",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37ff3872-319a-4927-b237-f08eed6baa79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.8,
        "y": 0.6
      },
      "kind": "metric",
      "text": "~300m Anxiety disorder sufferers in 2019",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb08f664-7b8a-4aa7-b5f1-354706494c63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.33,
        "w": 0.48,
        "x": 0.02,
        "y": 0.19
      },
      "kind": "table",
      "text": "PRODUCT: Deuterated etifoxine HCl oral dosage form (GRX-917); INDICATIONS: Lead: Anxiety Disorders; IP: Issued composition of matter; STATUS: Phase 1 completed, Phase 2 planned",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "413b038e-bda0-4203-87eb-7da3934eae6a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.02,
        "y": 0.12
      },
      "kind": "title",
      "text": "Designed to have rapid onset of anxiolytic activity but without the negative side effects seen with benzodiazepines",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f168e3a-d9e1-49a2-96b4-526f99f1591b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.02,
        "y": 0.06
      },
      "kind": "title",
      "text": "Product Overview: GRX-917 for Anxiety Disorders",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eccca105-96b6-47fa-af9a-3ccd4941bd9d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "b33152ba-fd6b-44d0-ac9d-d9f72f7a3bc2",
      "evidence": "Product Overview: GRX-917 for Anxiety Disorders",
      "confidence": 0.5
    },
    {
      "name": "Problem-Agitate-Solve (PAS)",
      "slug": "problem-agitate-solve-pas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "10171c73-1e80-4145-8a02-a9b18f393549",
      "evidence": "Anxiety disorders develop when feelings of apprehension and unease persist; 50% of US patients go untreated; No FDA approved novel treatments over the past decade",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 6,
      "beatId": "3567efa9-5c4b-4d3c-88d1-7a53a3a212bc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The presentation showcases the progress and achievements of atai Life Sciences' drug development programs, including efficacy and safety data.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 6,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "70da09d2-e8b7-478f-a3d9-ef5654b6b7c9",
      "evidence": "The presentation presents data and results from clinical trials, demonstrating the potential for atai Life Sciences' treatments to become first and best-in-class.",
      "position": 1,
      "objective": "Showcase the potential for first and best-in-class treatments",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}